glp-1 risks and side effects nausea: How to handle GLP-1s' most common effect Part 2 of a 3-Part

Salehi et al 16 found that a GLP-1 antagonist prevented surges in GLP-1 and reduced hypoglycemic episodes in patients with PGBH

The primary mechanism of action involves mimicking the naturally occurring hormone GLP-1, which is released from the intestines following food intake

The approval marks the 40th U.S

A brief history of the development of diabetes medications

Resources We Trust Cleveland Clinic: This Is How to Lose Weight the Right Way and Keep It Off Johns Hopkins Medicine: Maintaining Weight Loss Massachusetts General Hospital: Fitness for People Taking GLP-1 Agonists: A Comprehensive Guide WashU Medicine: Stopping GLP-1 Drugs Can Quickly Erase Cardiovascular Benefits Yale School of Medicine: What Is the Impact of GLP-1s in Older Adults With Obesity

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8